Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 60%GRADE not reported 0 · 0%Very low 1 · 20%Low 1 · 20%Moderate 0 · 0%High 0 · 0%

Levetiracetam vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Levetiracetam vs placebo

Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Levetiracetam vs placebo

Tardive dyskinesia: Deterioration of symptoms ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Levetiracetam vs placebo

Adverse effects ‐ any adverse effect · patients with antipsychotic‐induced tardive dyskinesia

ANTIEPILEPTIC ‐ LEVETIRACETAM showed no clear difference in adverse effects ‐ any adverse effect compared with PLACEBO (low certainty).

1 finding from 1 review

Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
RR 0.51 [0.25, 1.04]
1 study · 69 participants
Low

Levetiracetam vs placebo

Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether ANTIEPILEPTIC ‐ LEVETIRACETAM changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
RR 1.01 [0.46, 2.22]
2 studies · 119 participants
Very low